Citigroup’s SELLAS Life Sciences SLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-10
Closed -$1K 7787
2018
Q4
$1K Hold
10
﹤0.01% 7593
2018
Q3
$1K Hold
10
﹤0.01% 7679
2018
Q2
$2K Hold
10
﹤0.01% 7474
2018
Q1
$2K Buy
+10
New +$2.85K ﹤0.01% 7377
2017
Q4
Sell
-15
Closed -$8K 7640
2017
Q3
$8K Hold
15
﹤0.01% 6756
2017
Q2
$13K Sell
15
-1
-6% -$870 ﹤0.01% 6442
2017
Q1
$14K Buy
16
+4
+33% +$6.62K ﹤0.01% 6429
2016
Q4
$34K Buy
+12
New +$69.8K ﹤0.01% 6316

Other funds holding SLS

Citigroup's SLS Position: Q2 2026 in Review

Citigroup increased its SELLAS Life Sciences (SLS) stake by 1,173% in Q2 2026, buying an estimated $2.08M and bringing the position to 326,591 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Citigroup first reported a position in SLS in Q4 2016 and has held it in 15 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Citigroup held 326,591 shares of SELLAS Life Sciences worth $4.82M as of Q2 2026.
  • Citigroup bought 300,945 SELLAS Life Sciences shares in Q2 2026, an estimated $2.08M.
  • SELLAS Life Sciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2170 holding.
  • Citigroup first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 15 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.